Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Su

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2022
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and IIJutta Gärtner, Stephen L Hauser, Amit Bar-Or, et al.
Neurology and Therapy|May 3, 2022
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Neurology. Clinical Practice|February 5, 2026
Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America: Results From the EMPOwER StudyShuu-Jiun Wang, Artemio A Roxas, Bibiana Saravia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2024
Prognostic factors for worsening and improvement in multiple sclerosis using a multistate modelAlex Ocampo, Farhad Hatami, Jelena Čuklina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 1, 2022
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 yearsStephen L Hauser, Anne H Cross, Kevin Winthrop, et al.
Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2021
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 studyAmit Bar-Or, Heinz Wiendl, Xavier Montalban, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2022
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and IIJutta Gärtner, Stephen L Hauser, Amit Bar-Or, et al.
Neurology and Therapy|May 3, 2022
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Neurology. Clinical Practice|February 5, 2026
Effect of Erenumab on Patient-Reported Outcomes in Episodic Migraine in Asia, the Middle East, and Latin America: Results From the EMPOwER StudyShuu-Jiun Wang, Artemio A Roxas, Bibiana Saravia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2024
Prognostic factors for worsening and improvement in multiple sclerosis using a multistate modelAlex Ocampo, Farhad Hatami, Jelena Čuklina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 1, 2022
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 yearsStephen L Hauser, Anne H Cross, Kevin Winthrop, et al.
Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2021
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 studyAmit Bar-Or, Heinz Wiendl, Xavier Montalban, et al.
Pageof 5